Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advinus sets up US operations

This article was originally published in Scrip

Executive Summary

Advinus Therapeutics, an Indian contract research services and discovery company, has commenced operations in the US. It has set up a wholly owned subsidiary, Advinus Therapeutics , with an office in Research Triangle Park, North Carolina. Advinus expects the US operations to help the company build on its client base and collaborations and also expand into new ones. Advinus already has a string of R&D alliances with Merck & Co, Ortho-McNeil-Janssen Pharmaceuticals and the Drugs for Neglected Diseases initiative, Geneva, among others. Advinus, which is part of India's diversified Tata group, has also appointed Dr Eric Nelson as global head of business development, marketing and strategy. Dr Nelson, who will be based out of the company's US office and will manage its operations there, joins Advinus from Tranzyme Pharma where he was vice president of business development and licensing.

You may also be interested in...

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

India-China Tango: Can Gland Sustain Listing Luster?

Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?

A Peek At How Janssen’s Supply Chain Withstood COVID-19 Disruptions

A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts